# Hadassah Medical Center

Source: https://onco.cc/institutions/hadassah/  
OnCo record `hadassah` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jerusalem's university hospital and Sharett Institute of Oncology, known for in-house CAR-T, BRCA founder mutation research and melanoma immunotherapy.

## Summary

Hadassah Medical Center's Ein Kerem and Mount Scopus campuses house the Sharett Institute of Oncology and the Hebrew University's medical faculty. Polina Stepensky's bone marrow transplantation and immunotherapy department manufactures its own CD19 and BCMA CAR-T products, making Hadassah one of the first hospitals worldwide to deliver academic point-of-care CAR-T at scale; Michal Lotem's melanoma unit has long run tumour vaccine and immunotherapy trials, Tamar Peretz's oncogenetics group characterised BRCA founder mutations in Ashkenazi Jewish populations, and Aron Popovtzer leads head and neck oncology. The centre provides radiotherapy, gamma knife, paediatric haemato-oncology and a phase 1 unit for Jerusalem and the surrounding region.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Hadassah University Hospital; Sharett Institute of Oncology; Hadassah Ein Kerem
- City: Jerusalem, IL
- Type: hospital
- Website: https://www.hadassah.org.il/en/

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hadassah_Medical_Center
- Homepage: https://www.hadassah.org.il/en/
- Sharett Institute of Oncology: https://www.hadassah.org.il/en/departments/sharett-institute-of-oncology/

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Melanoma](https://onco.cc/cancers/melanoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [CD19](https://onco.cc/targets/cd19/)
- institutions: [Hebrew University of Jerusalem](https://onco.cc/institutions/hebrew-university-of-jerusalem/), [Shaare Zedek Medical Center](https://onco.cc/institutions/shaare-zedek/), [Sheba Medical Center](https://onco.cc/institutions/sheba/), [Soroka University Medical Center](https://onco.cc/institutions/soroka-medical-center/)
- people: [Polina Stepensky](https://onco.cc/people/polina-stepensky/), [Yechezkel Barenholz](https://onco.cc/people/yechezkel-barenholz/), [Yoram G. Weiss](https://onco.cc/people/yoram-weiss/)
- bottlenecks: [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/), [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- trials: [HBI0101 (NXC-201) multiple myeloma phase 1](https://onco.cc/trials/nxc-201-mm/)
- key papers: [Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)](https://onco.cc/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/)

---
JSON: https://onco.cc/api/v1/entities/hadassah.json